Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM6UC8Y)

Drug Name
N-(3-(trifluoromethoxy)benzyl)-4-phenoxybenzamide Drug Info
Synonyms CHEMBL198832; N-(3-(trifluoromethoxy)benzyl)-4-phenoxybenzamide
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
44405454
TTD Drug ID
DM6UC8Y

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting Stress-activated protein kinase 2a (p38 alpha)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ozagrel DMIGKA1 Xerophthalmia 5B55.Y Phase 4 [2]
Losmapimod DMIL37Z Acute coronary syndrome BA41 Phase 3 [2]
VX-702 DMKJDR6 Coronary artery disease BA80 Phase 2a [3]
VX-745 DMJAEG6 Alzheimer disease 8A20 Phase 2 [4]
Dilmapimod DMBYJ92 Acute lung injury NB32.3 Phase 2 [2]
PMID25991433-Compound-A1 DM89LF0 N. A. N. A. Patented [5]
PMID25991433-Compound-F2 DM37VIQ N. A. N. A. Patented [5]
PMID25991433-Compound-L2 DM58UO9 N. A. N. A. Patented [5]
PMID25991433-Compound-L3 DM3LWUR N. A. N. A. Patented [5]
PMID25991433-Compound-L1 DM2135Y N. A. N. A. Patented [5]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Stress-activated protein kinase 2a (p38 alpha) TTQBR95 MK14_HUMAN Inhibitor [1]

References

1 Two classes of p38alpha MAP kinase inhibitors having a common diphenylether core but exhibiting divergent binding modes. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5274-9.
2 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
3 Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum. 2009 May;60(5):1232-41.
4 Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5.
5 c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.